Short answer
RxSight, Inc. (RXST) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for three months ended June 30, 2026.
RxSight, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for three months ended June 30, 2026
- Press release issued August 5, 2026
- Detailed operating results and financial condition in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $33.7M, including $6.5M Alcon collaboration revenue; product sales fell 19% to $27.2M
- Product gross margin declined to 71.2% from 74.9%; total margin reached 76.7% with collaboration revenue
- GAAP net loss widened to $12.1M, or $0.29 per share, from $11.8M; adjusted loss reached $4.6M
- Cash, equivalents and short-term investments totaled $208.8M, supporting near-term development and commercial investment
- 2026 guidance withdrawn following CEO transition; formal outlook expected to resume in early 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RxSight, Inc. 8-K filings
Get the next RXST 8-K as it lands
Follow RXST for push alerts, or ask the research agent what this filing means.